KRYS News and Press, Krystal Biotech Inc. From 02/15/19

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...

Phase I/II Study KRYS data by YCharts In early October, Krystal Biotech ( KRYS ) reported impressive data from its phase I/II gene therapy trial investigating KB103 as a treatment for dystrophic epidermolysis bulossa ((DEB)), a genetic condition characterized by severe chronic blis...

Introduction In my last article, I outlined the broader investment opportunity in Krystal Biotech ( KRYS ), a unique gene therapy company focused on dermatological conditions. In that article, I gave a surface level overview of their STAR-D (Skin TARgeted Delivery) gene therapy platform...

PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman a...

Announced positive interim results from randomized placebo-controlled Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa PITTSBURGH, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (Nasdaq: KRYS), a gene ther...

Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in...

The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...

PITTSBURGH, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman a...

KB105 is Krystal’s second "off-the-shelf" topical gene therapy candidate to receive Rare Pediatric Disease Designation for treating debilitating skin diseases PITTSBURGH, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS), a gene therapy company dedicated to...

NEW YORK , Aug. 17, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as sole placement agent in Krystal Biotech, Inc.'s (NASDAQ: KRYS) securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at ...